



**21 February 2013**

**ASX RELEASE**

## **Novogen demerger – tax implications**

The demerger of Novogen and MEI Pharma is now complete. IRS Form 8937, together with a report for all shareholders on the tax implications of the demerger, are now available on the Novogen website [www.novogen.com/](http://www.novogen.com/)

### **About Novogen**

Novogen Ltd is a public Australian biotechnology company whose shares trade on both the Australian Stock Exchange (symbol 'NRT') and NASDAQ (symbol 'NVGN'). The Company is based in Sydney, Australia and is focused on the development of a family of novel anti-cancer drugs based on super-benzopyran and 'stealth' drug technologies. The Company's inaugural drug candidate is CS-6.

### **About CS-6**

CS-6 belongs to a new class of drug candidates intended to treat most forms of cancer in a comprehensive manner, targeting both cancer cells and their progenitors, the cancer stem cells. CS-6 shows broad anti-proliferative and cytotoxic activity against human cancer cells, with particular activity against human glioblastoma cells. CS-6 also has been designed deliberately to meet the major known criteria for crossing the blood-brain barrier, and for that reason is being developed as a first-line for the treatment of glioblastoma multiforme, the main form of primary brain cancer.

### **Further information**

Contact Dr Graham Kelly, Chief Executive Officer.

T: (61 2) 9878 0088

M: (61) 0459 200 095

E: [Graham.Kelly@novogen.com](mailto:Graham.Kelly@novogen.com)

Further information is available on the Company's web site, [www.novogen.com](http://www.novogen.com)